跳至主要内容
临床试验/NCT00694928
NCT00694928已完成3 期

Vaginal Infection Study 2

Lumara Health, Inc.73 个研究点 分布在 2 个国家目标入组 843 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
843
试验地点
73
主要终点
Clinical symptom resolution

研究概览

简要总结

This study will evaluate the efficacy and safety of a vaginal product compared with that of another vaginal product in the treatment of vaginal infections.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients must have a clinical diagnosis of vaginal infection.
  • Patients must be post-menopausal, surgically sterilized or using an acceptable form of birth control.

排除标准

  • Patients must not have any other infections
  • May not be pregnant or nursing
  • May not be receiving any other antimicrobial therapies or any medications that would interfere with the outcome of the study.

研究组 & 干预措施

1

Experimental

clindamycin phosphate/butoconazole nitrate

干预措施: clindamycin phosphate/butoconazole nitrate (Drug)

2

Active Comparator

butoconazole nitrate

干预措施: butoconazole nitrate (Drug)

结局指标

主要结局

Clinical symptom resolution

时间窗: baseline, 7 to 10 days and 21 to 30 days

次要结局

  • Yeast Culture for Candida(baseline, 7 to 10 days and 21 to 30 days)
  • Gram Stain Nugent Score(baseline, 7 to 10 days and 21 to 30 days)
  • Saline wet mount for clue cells(baseline, 7 to 10 days and 21 to 30 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (73)

Loading locations...

相似试验

Vaginal Infection Study 2 | 临床试验